1. O’Dwyer PJ, Stevenson JP, Johnson SW. Clinical status of cisplatin, carboplatin, and other platinum-based antitumor drugs. In: Lippert B, editor. Cisplatin. Chemistry and biochemistry of a leading anticancer drug. Zürich, Weinheim: VHCA, Wiley-VCH; 1999. p. 31–72.
2. Reedijk J. Improved understanding in platinum antitumour chemistry. Chem Commun 1996:801–6.
3. Farrell N. Current status of structure–activity relationships of platinum anticancer drugs: activation of the trans geometry. In: Sigel A, Sigel H, editors. Metal ions in biological systems, vol. 32. New York, Basel, Hong Kong: Marcel Dekker, Inc.; 1996. p. 603–39.
4. Current status of the development of trans-platinum antitumor drugs;Perez;Crit. Rev. Oncol. Hematol.,2000
5. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair;Brabec;Prog. Nucl. Acid Res. Mol. Biol.,2002